Guidelines on the investigation and management of antiphospholipid syndrome

British Journal of Haematology

Volumn 157, Issue 1, 2012, Pages 47-58

  Keeling, David ^a   Mackie, Ian ^b   Moore, Gary W ^c   Greer, Ian A ^d   Greaves, Michael ^e  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Antiphospholid antibodies; Antiphospholipid syndrome; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTIVITAMIN K; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; HEPARIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PLACEBO; PROTHROMBIN ANTIBODY; WARFARIN;

ANTIBODY DETECTION; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLOOD SAMPLING; BRAIN ISCHEMIA; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CLINICAL LABORATORY; DEEP VEIN THROMBOSIS; DILUTE RUSSELL VIPER VENOM TIME; DRUG DOSE INCREASE; DRUG INDICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS WASTAGE; HEART INFARCTION; HEMATOLOGICAL PARAMETERS; HEMATOLOGICAL PROCEDURES; HUMAN; INCIDENTAL FINDING; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EMBOLISM; MULTIPLE SCLEROSIS; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PLATELET NEUTRALIZATION PROCEDURE; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY DISORDER; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTHROMBIN TIME; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SPONTANEOUS ABORTION; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT CONTRAINDICATION; VEIN THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; HUMANS;

EID: 84858283382     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09037.x     Document Type: Article

References (122)

1. 2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood, 116, 1336-1343.
2. Altman, D.G. (1991) Practical Statistics for Medical Research. Chapman & Hall, London.
3. Amengual, O., Atsumi, T., Khamashta, M.A. & Hughes, G.R. (1998) The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thrombosis and Haemostasis, 79, 276-281.
4. Atsumi, T., Khamashta, M.A., Amengual, O., Donohoe, S., Mackie, I., Ichikawa, K., Koike, T. & Hughes, G.R. (1998a) Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clinical and Experimental Immunology, 112, 325-333.
5. Atsumi, T., Khamashta, M.A., Andujar, C., Leandro, M.J., Amengual, O., Ames, P.R. & Hughes, G.R. (1998b) Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. Journal of Rheumatology, 25, 69-73.
6. Bertolaccini, M.L., Atsumi, T., Escudero Contreras, A., Khamashta, M.A. & Hughes, G.R. (2001) The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. Journal of Rheumatology, 28, 2637-2643.
7. Bevers, E.M., Galli, M., Barbui, T., Comfurius, P. & Zwaal, R.F. (1991) Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thrombosis and Haemostasis, 66, 629-632.
8. Blank, M., Cohen, J., Toder, V. & Shoenfeld, Y. (1991) Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proceedings of the National Academy of Sciences of the United States of America, 88, 3069-3073.
9. Bongard, O., Reber, G., Bounameaux, H. & de Moerloose, P. (1992) Anticardiolipin antibodies in acute venous thromboembolism [letter]. Thrombosis and Haemostasis, 67, 724.
10. Branch, W. (2011) Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010. Lupus, 20, 158-164.
11. Branch, D.W. & Rodgers, G.M. (1993) Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. American Journal of Obstetrics and Gynecology, 168, 206-210.
12. Branch, D.W., Porter, T.F., Rittenhouse, L., Caritis, S., Sibai, B., Hogg, B., Lindheimer, M.D., Klebanoff, M., MacPherson, C., VanDorsten, J.P., Landon, M., Paul, R., Miodovnik, M., Meis, P. & Thurnau, G. (2001) Antiphospholipid antibodies in women at risk for preeclampsia. American Journal of Obstetrics and Gynecology, 184, 825-832; discussion 832-824.
13. Briggs, C., Guthrie, D., Hyde, K., Mackie, I., Parker, N., Popek, M., Porter, N. & Stephens, C. (2008) Guidelines for point-of-care testing: haematology. British Journal of Haematology, 142, 904-915.
14. Buckingham, K.L. & Chamley, L.W. (2009) A critical assessment of the role of antiphospholipid antibodies in infertility. Journal of Reproductive Immunology, 80, 132-145.
15. Cavestro, C., Micca, G., Molinari, F., Bazzan, M., C, D.I.P., Aloi, R., Pedemonte, E., Iannini, R., Frigeri, M.C. & Roccatello, D. (2011) Migraineurs show a high prevalence of antiphospholipid antibodies. Journal of Thrombosis and Haemostasis, 9, 1350-1354.
16. Cervera, R., Piette, J.C., Font, J., Khamashta, M.A., Shoenfeld, Y., Camps, M.T., Jacobsen, S., Lakos, G., Tincani, A., Kontopoulou-Griva, I., Galeazzi, M., Meroni, P.L., Derksen, R.H., de Groot, P.G., Gromnica-Ihle, E., Baleva, M., Mosca, M., Bombardieri, S., Houssiau, F., Gris, J.C., Quere, I., Hachulla, E., Vasconcelos, C., Roch, B., Fernandez-Nebro, A., Boffa, M.C., Hughes, G.R. & Ingelmo, M. (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients. Arthritis and Rheumatism, 46, 1019-1027.
17. Cervera, R., Bucciarelli, S., Plasin, M.A., Gomez-Puerta, J.A., Plaza, J., Pons-Estel, G., Shoenfeld, Y., Ingelmo, M. & Espinos, G. (2009) Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". Journal of Autoimmunity, 32, 240-245.
18. Chamley, L.W., Duncalf, A.M., Mitchell, M.D. & Johnson, P.M. (1998) Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet, 352, 1037-1038.
19. Clyne, L.P., Yen, Y., Kriz, N.S. & Breitenstein, M.G. (1993) The lupus anticoagulant. High incidence of 'negative' mixing studies in a human immunodeficiency virus-positive population. Archives of Pathology and Laboratory Medicine, 117, 595-601.
20. Cowchock, S. & Reece, E.A. (1997) Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizang Group of the Antiphospholipid Antibody Treatment Trial. American Journal of Obstetrics and Gynecology, 176, 1099-1100.
21. Crowther, M.A., Ginsberg, J.S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., Clarke, A., Geerts, W., Forgie, M., Green, D., Costantini, L., Yacura, W., Wilson, S., Gent, M. & Kovacs, M.J. (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. New England Journal of Medicine, 349, 1133-1138.
22. 2-Glycoprotein I: evolution, structure and function. Journal of Thrombosis and Haemostasis, 9, 1275-1284.
23. de Groot, P.G., Lutters, B., Derksen, R.H., Lisman, T., Meijers, J.C. & Rosendaal, F.R. (2005) Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. Journal of Thrombosis and Haemostasis, 3, 1993-1997.
24. 2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood, 104, 3598-3602.
25. de Laat, B., Derksen, R.H., Urbanus, R.T. & de Groot, P.G. (2005) IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood, 105, 1540-1545.
26. Denis-Magdelaine, A., Flahault, A. & Verdy, E. (1995) Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants. Haemostasis, 25, 98-105.
27. Derksen, R.H., de Groot, P.G. & Kappelle, L.J. (2003) Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. Neurology, 61, 111-114.
28. Edwards, M.H., Pierangeli, S., Liu, X., Barker, J.H., Anderson, G. & Harris, E.N. (1997) Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation, 96, 4380-4384.
29. Empson, M.B., Lassere, M., Craig, J.C. & Scott, J.R. (2005) Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD002859. DOI: 10.1002/14651858.CD002859.pub2.
30. Erkan, D., Harrison, M.J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., Unalp-Arida, A., Vilela, V., Yazici, Y. & Lockshin, M.D. (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis and Rheumatism, 56, 2382-2391.
31. Espinola, R.G., Pierangeli, S.S., Gharavi, A.E. & Harris, E.N. (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thrombosis and Haemostasis, 87, 518-522.
32. Exner, T. (2000) Conceptions and misconceptions in testing for lupus anticoagulants. Journal of Autoimmunity, 15, 179-183.
33. Farquharson, R.G., Quenby, S. & Greaves, M. (2002) Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstetrics and Gynecology, 100, 408-413.
34. Favaloro, E.J. (2007) Preanalytical variables in coagulation testing. Blood Coagulation and Fibrinolysis, 18, 86-89.
35. Ferrara, D.E., Liu, X., Espinola, R.G., Meroni, P.L., Abukhalaf, I., Harris, E.N. & Pierangeli, S.S. (2003) Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis and Rheumatism, 48, 3272-3279.
36. Ferrara, D.E., Swerlick, R., Casper, K., Meroni, P.L., Vega-Ostertag, M.E., Harris, E.N. & Pierangeli, S.S. (2004) Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. Journal of Thrombosis and Haemostasis, 2, 1558-1563.
37. Finazzi, G., Marchioli, R., Brancaccio, V., Schinco, P., Wisloff, F., Musial, J., Baudo, F., Berrettini, M., Testa, S., D'Angelo, A., Tognoni, G. & Barbui, T. (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Journal of Thrombosis and Haemostasis, 3, 848-853.
38. Galli, M., Comfurius, P., Maassen, C., Hemker, H.C., de Baets, M.H., van Breda Vriesman, P.J., Barbui, T., Zwaal, R.F. & Bevers, E.M. (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor [see comments]. Lancet, 335, 1544-1547.
39. Galli, M., Luciani, D., Bertolini, G. & Barbui, T. (2003a) Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood, 102, 2717-2723.
40. Galli, M., Luciani, D., Bertolini, G. & Barbui, T. (2003b) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood, 101, 1827-1832.
41. Galli, M., Borrelli, G., Jacobsen, E.M., Marfisi, R.M., Finazzi, G., Marchioli, R., Wisloff, F., Marziali, S., Morboeuf, O. & Barbui, T. (2007) Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood, 110, 1178-1183.
42. Gardiner, C., Mackie, I.J., Malia, R.G., Jones, D.W., Winter, M., Leeming, D., Taberner, D.A., Machin, S.J. & Greaves, M. (2000) The importance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant. British Journal of Haematology, 111, 1230-1235.
43. Giannakopoulos, B. & Krilis, S.A. (2009) How I treat the antiphospholipid syndrome. Blood, 114, 2020-2030.
44. Giannakopoulos, B., Passam, F., Rahgozar, S. & Krilis, S.A. (2007) Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood, 109, 422-430.
45. Giannakopoulos, B., Passam, F., Ioannou, Y. & Krilis, S.A. (2009) How we diagnose the antiphospholipid syndrome. Blood, 113, 985-994.
46. Ginsberg, J.S., Brill-Edwards, P., Johnston, M., Denburg, J.A., Andrew, M., Burrows, R.F., Bensen, W., Cividino, A. & Long, A.A. (1992) Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood, 80, 975-980.
47. Ginsburg, K.S., Liang, M.H., Newcomer, L., Goldhaber, S.Z., Schur, P.H., Hennekens, C.H. & Stampfer, M.J. (1992) Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis [see comments]. Annals of Internal Medicine, 117, 997-1002.
48. Girardi, G., Redecha, P. & Salmon, J.E. (2004) Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nature Medicine, 10, 1222-1226.
49. Giron-Gonzalez, J.A., Garcia del Rio, E., Rodriguez, C., Rodriguez-Martorell, J. & Serrano, A. (2004) Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. Journal of Rheumatology, 31, 1560-1567.
50. Greaves, M., Cohen, H., MacHin, S. & Mackie, I. (2000) Guidelines on the investigation and management of the antiphospholipid syndrome. British Journal Haematology, 109, 704-715.
51. Greer, I.A. & Nelson-Piercy, C. (2005) Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood, 106, 401-407.
52. Heinzlef, O., Weill, B., Johanet, C., Sazdovitch, V., Caillat-Zucman, S., Tournier-Lasserve, E. & Roullet, E. (2002) Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. Journal of Neurology, Neurosurgery and Psychiatry, 72, 647-649.
53. Horowitz, G.L., Altaie, S., Boyd, J.C., Ceriotti, F., Garg, U., Horn, P., Pesce, A., Sine, H.E. & Zakowski, J. (2008) Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory: Approved Guideline - Third Edition. CLSI document C28-A3c. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
54. Hughes, G.R. (2003) Migraine, memory loss, and "multiple sclerosis". Neurological features of the antiphospholipid (Hughes') syndrome. Postgraduate Medical Journal, 79, 81-83.
55. Hughes, G.R. & Khamashta, M.A. (2003) Seronegative antiphospholipid syndrome. Annals of the Rheumatic Diseases, 62, 1127.
56. Ichikawa, K., Tsutsumi, A., Atsumi, T., Matsuura, E., Kobayashi, S., Hughes, G.R., Khamashta, M.A. & Koike, T. (1999) A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies. Arthritis and Rheumatism, 42, 2461-2470.
57. Iorio, A., Kearon, C., Filippucci, E., Marcucci, M., Macura, A., Pengo, V., Siragusa, S. & Palareti, G. (2010) Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Archives of Internal Medicine, 170, 1710-1716.
58. Jouhikainen, T. (1990) Detection of lupus anticoagulant by means of dilute Russell's viper venom time is affected by oral anticoagulant therapy. Blood Coagulation and Fibrinolysis, 1, 627-632.
59. Kearon, C., Kahn, S.R., Agnelli, G., Goldhaber, S., Raskob, G.E. & Comerota, A.J. (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 454S-545S.
60. Khamashta, M.A., Cuadrado, M.J., Mujic, F., Taub, N.A., Hunt, B.J. & Hughes, G.R. (1995) The management of thrombosis in the antiphospholipid-antibody syndrome [see comments]. New England Journal of Medicine, 332, 993-997.
61. Krnic-Barrie, S., O'Connor, C.R., Looney, S.W., Pierangeli, S.S. & Harris, E.N. (1997) A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Archives of Internal Medicine, 157, 2101-2108.
62. Kutteh, W.H. & Ermel, L.D. (1996) A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. American Journal of Reproductive Immunology, 35, 402-407.
63. Laskin, C.A., Bombardier, C., Hannah, M.E., Mandel, F.P., Ritchie, J.W., Farewell, V., Farine, D., Spitzer, K., Fielding, L., Soloninka, C.A. & Yeung, M. (1997) Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. New England Journal of Medicine, 337, 148-153.
64. Laskin, C.A., Spitzer, K.A., Clark, C.A., Crowther, M.R., Ginsberg, J.S., Hawker, G.A., Kingdom, J.C., Barrett, J. & Gent, M. (2009) Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. Journal of Rheumatology, 36, 279-287.
65. Lawrie, A.S., Mackie, I.J., Purdy, G. & Machin, S.J. (1999) The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers. Thrombosis and Haemostasis, 81, 758-762.
66. Levine, S.R., Brey, R.L., Tilley, B.C., Thompson, J.L., Sacco, R.L., Sciacca, R.R., Murphy, A., Lu, Y., Costigan, T.M., Rhine, C., Levin, B., Triplett, D.A. & Mohr, J.P. (2004) Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA, 291, 576-584.
67. Liestol, S., Jacobsen, E.M. & Wisloff, F. (2002) Dilute prothrombin time-based lupus ratio test. Integrated LA testing with recombinant tissue thromboplastin. Thrombosis Research, 105, 177-182.
68. Lim, W., Crowther, M.A. & Eikelboom, J.W. (2006) Management of antiphospholipid antibody syndrome: a systematic review. JAMA, 295, 1050-1057.
69. Male, C., Lechner, K., Speiser, W. & Pabinger, I. (2000) Transient lupus anticoagulants in children: stepwise disappearance of diagnostic features. Thrombosis and Haemostasis, 83, 174-175.
70. Malia, R.G., Kitchen, S., Greaves, M. & Preston, F.E. (1990) Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies [see comments]. British Journal Haematology, 76, 101-107.
71. McNeil, H.P., Simpson, R.J., Chesterman, C.N. & Krilis, S.A. (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proceedings of the National Academy of Sciences of the United States of America, 87, 4120-4124.
72. Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., Derksen, R.H., de Groot, P.G., Koike, T., Meroni, P.L., Reber, G., Shoenfeld, Y., Tincani, A., Vlachoyiannopoulos, P.G. & Krilis, S.A. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 4, 295-306.
73. Montalban, J., Cervera, R., Font, J., Ordi, J., Vianna, J., Haga, H.J., Tintore, M., Khamashta, M.A. & Hughes, G.R. (1992) Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus. Neurology, 42, 681-682.
74. Moore, G.W. & Savidge, G.F. (2004) Heterogeneity of Russell's viper venom affects the sensitivity of the dilute Russell's viper venom time to lupus anticoagulants. Blood Coagulation and Fibrinolysis, 15, 279-282.
75. Moore, G.W. & Savidge, G.F. (2006) The dilution effect of equal volume mixing studies compromises confirmation of inhibition by lupus anticoagulants even when mixture specific reference ranges are applied. Thrombosis Research, 118, 523-528.
76. Moore, G.W., Smith, M.P. & Savidge, G.F. (2003) The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants. Blood Coagulation and Fibrinolysis, 14, 307-312.
77. Moore, G.W., Rangarajan, S., Holland, L.J., Henley, A. & Savidge, G.F. (2005) Low frequency of elevated prothrombin times in patients with lupus anticoagulants when using a recombinant thromboplastin reagent: implications for dosing and monitoring of oral anticoagulant therapy. British Journal of Biomedical Science, 62, 15-18; quiz 47.
78. Naess, I.A., Christiansen, S.C., Cannegieter, S.C., Rosendaal, F.R. & Hammerstroem, J. (2006) A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). Journal of Thrombosis and Haemostasis, 4, 44-49.
79. Nelson, S.M. & Greer, I.A. (2008) The potential role of heparin in assisted conception. Human Reproduction Update, 14, 623-645.
80. Noble, L.S., Kutteh, W.H., Lashey, N., Franklin, R.D. & Herrada, J. (2005) Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertility and Sterility, 83, 684-690.
81. Oger, E., Lernyer, C., Dueymes, M., Le Moigne, E., Bressolette, L., Escoffre, M., Youinou, P. & Mottier, D. (1997) Association between IgM anticardiolipin antibodies and deep venous thrombosis in patients without systemic lupus erythematosus. Lupus, 6, 455-461.
82. Oku, K., Atsumi, T., Bohgaki, M., Amengual, O., Kataoka, H., Horita, T., Yasuda, S. & Koike, T. (2009) Complement activation in patients with primary antiphospholipid syndrome. Annals of the Rheumatic Diseases, 68, 1030-1035.
83. Okuma, H., Kitagawa, Y., Yasuda, T., Tokuoka, K. & Takagi, S. (2010) Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. International Journal of Medical Sciences, 7, 15-18.
84. Olteanu, H., Downes, K.A., Patel, J., Praprotnik, D. & Sarode, R. (2009) Warfarin does not interfere with lupus anticoagulant detection by dilute Russell's viper venom time. Clinical laboratory, 55, 138-142.
85. Opatrny, L., David, M., Kahn, S.R., Shrier, I. & Rey, E. (2006) Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. Journal of Rheumatology, 33, 2214-2221.
86. Parmar, K., Lefkou, E., Doughty, H., Connor, P. & Hunt, B.J. (2009) The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in individuals receiving or not receiving an oral vitamin K antagonist. Blood Coagulation and Fibrinolysis, 20, 271-275.
87. Pattison, N.S., Chamley, L.W., Birdsall, M., Zanderigo, A.M., Liddell, H.S. & McDougall, J. (2000) Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. American Journal of Obstetrics and Gynecology, 183, 1008-1012.
88. Pengo, V., Tripodi, A., Reber, G., Rand, J.H., Ortel, T.L., Galli, M. & De Groot, P.G. (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 7, 1737-1740.
89. Pengo, V., Ruffatti, A., Legnani, C., Gresele, P., Barcellona, D., Erba, N., Testa, S., Marongiu, F., Bison, E., Denas, G., Banzato, A., Padayattil Jose, S. & Iliceto, S. (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 8, 237-242.
90. Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., De Micheli, V., Gresele, P., Tonello, M., Ghirarduzzi, A., Bison, E., Denas, G., Banzato, A., Padayattil Jose, S. & Iliceto, S. (2011) Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multicenter prospective study. Blood, 118, 4714-4718.
91. Perry, D.J., Fitzmaurice, D.A., Kitchen, S., Mackie, I.J. & Mallett, S. (2010) Point-of-care testing in haemostasis. British Journal of Haematology, 150, 501-514.
92. Pierangeli, S.S. & Harris, E.N. (2008) A protocol for determination of anticardiolipin antibodies by ELISA. Nature Protocols, 3, 840-848.
93. Rai, R.S., Clifford, K., Cohen, H. & Regan, L. (1995) High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Human Reproduction, 10, 3301-3304.
94. Rai, R., Cohen, H., Dave, M. & Regan, L. (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ, 314, 253-257.
95. Rand, J.H., Wu, X.X., Andree, H.A., Ross, J.B., Rusinova, E., Gascon-Lema, M.G., Calandri, C. & Harpel, P.C. (1998) Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood, 92, 1652-1660.
96. Rand, J.H., Wu, X.X., Quinn, A.S., Chen, P.P., Hathcock, J.J. & Taatjes, D.J. (2008) Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood, 112, 1687-1695.
97. Reber, G., Boehlen, F. & de Moerloose, P. (2008) Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream? Seminars in Thrombosis and Hemostasis, 34, 340-346.
98. Robertson, B. & Greaves, M. (2006) Antiphospholipid syndrome: an evolving story. Blood Reviews, 20, 201-212.
99. Robertson, L., Wu, O., Langhorne, P., Twaddle, S., Clark, P., Lowe, G.D., Walker, I.D., Greaves, M., Brenkel, I., Regan, L. & Greer, I.A. (2006) Thrombophilia in pregnancy: a systematic review. British Journal Haematology, 132, 171-196.
100. Rosborough, T.K., Jacobsen, J.M. & Shepherd, M.F. (2010) Factor X and factor II activity levels do not always agree in warfarin-treated lupus anticoagulant patients. Blood Coagulation and Fibrinolysis, 21, 242-244.
101. Rosove, M.H. & Brewer, P.M. (1992) Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Annals of Internal Medicine, 117, 303-308.
102. Ruiz-Irastorza, G., Hunt, B.J. & Khamashta, M.A. (2007) A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis and Rheumatism, 57, 1487-1495.
103. Sacre, K., Brihaye, B., Hyafil, F., Serfaty, J.M., Escoubet, B., Zennaro, M.C., Lidove, O., Laissy, J.P. & Papo, T. (2010) Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study. Arthritis and Rheumatism, 62, 2093-2100.
104. Salmon, J.E. & Girardi, G. (2004) The role of complement in the antiphospholipid syndrome. Current Directions in Autoimmunity, 7, 133-148.
105. Samarkos, M., Davies, K.A., Gordon, C. & Loizou, S. (2006) Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clinical Rheumatology, 25, 199-204.
106. Schjetlein, R., Sletnes, K.E. & Wisloff, F. (1993) A quantitative, semi-automated and computer-assisted test for lupus anticoagulant. Thrombosis Research, 69, 239-250.
107. Schulman, S., Svenungsson, E. & Granqvist, S. (1998) Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. American Journal of Medicine, 104, 332-338.
108. Shamonki, J.M., Salmon, J.E., Hyjek, E. & Baergen, R.N. (2007) Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. American Journal of Obstetrics and Gynecology, 196, 167 e161-165.
109. Simioni, P., Sanson, B., Prandoni, P., Tormene, D., Friederich, P., Girolami, B., Gavasso, S., Huisman, M., Buller, H., Wouter ten Cate, J., Girolami, A. & Prins, M. (1999) Incidence of venous thromboembolism in families with inherited thrombophilia. Thrombosis and Haemostasis, 81, 198-202.
110. Sletnes, K.E., Gravem, K. & Wisloff, F. (1992) Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies. Thrombosis Research, 66, 43-53.
111. Stegnar, M., Bozic, B., Peternel, P., Kveder, T., Vene, N. & Rozman, B. (1991) Prevalence of antiphospholipid antibodies in deep vein thrombosis and their relationship to blood coagulation and fibrinolysis. Thrombosis Research, 63, 433-443.
112. Stephenson, M.D., Ballem, P.J., Tsang, P., Purkiss, S., Ensworth, S., Houlihan, E. & Ensom, M.H. (2004) Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. Journal of Obstetrics and Gynaecology Canada, 26, 729-734.
113. Swadzba, J., Iwaniec, T., Pulka, M., De Laat, B., De Groot, P.G. & Musial, J. (2011) Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines. Journal of Thrombosis and Haemostasis, 9, 1776-1783.
114. Thom, J., Ivey, L. & Eikelboom, J. (2003) Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. Journal of Thrombosis and Haemostasis, 1, 2689-2691.
115. Tietjen, G.E., Day, M., Norris, L., Aurora, S., Halvorsen, A., Schultz, L.R. & Levine, S.R. (1998) Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study. Neurology, 50, 1433-1440.
116. Tincani, A., Allegri, F., Balestrieri, G., Reber, G., Sanmarco, M., Meroni, P. & Boffa, M.C. (2004) Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thrombosis Research, 114, 553-558.
117. Topping, J., Quenby, S., Farquharson, R., Malia, R. & Greaves, M. (1999) Marked variation in antiphospholipid antibodies during pregnancy: relationships to pregnancy outcome. Human Reproduction, 14, 224-228.
118. Tripodi, A., Chantarangkul, V., Clerici, M., Negri, B., Galli, M. & Mannucci, P.M. (2001) Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. British Journal Haematology, 115, 672-678.
119. Tulppala, M., Marttunen, M., Soderstrom-Anttila, V., Foudila, T., Ailus, K., Palosuo, T. & Ylikorkala, O. (1997) Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Human Reproduction, 12, 1567-1572.
120. Urbanus, R.T., Siegerink, B., Roest, M., Rosendaal, F.R., de Groot, P.G. & Algra, A. (2009) Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurology, 8, 998-1005.
121. Vila, P., Hernandez, M.C., Lopez-Fernandez, M.F. & Batlle, J. (1994) Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thrombosis and Haemostasis, 72, 209-213.
122. Zoghlami-Rintelen, C., Vormittag, R., Sailer, T., Lehr, S., Quehenberger, P., Rumpold, H., Male, C. & Pabinger, I. (2005) The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. Journal of Thrombosis and Haemostasis, 3, 1160-1165.